COVID-19 Treatments: Hydroxych loroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier)

7/9

Meta

Early, Late

Raoult et al., Preprint (Preprint) (meta analysis - not included in study count)

Hydroxych loroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier)

Updated meta analysis showing significant reductions in mortality and viral shedding. Mortality OR 0.53 [0.4-0.71] for clinical studies, 0.92 big data studies, 18,211 patients. Persistent viral shedding OR 0.47 [0.28-0.79], 4,540 patients.

Source

See all 143 studies

Please send us corrections, updates, or comments.

Submit